SCHEMBL23923170

SCHEMBL23923170

CCOC(=O)CCc1cccc(=O)n1CC(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.47
ALDH1A1 P00352 8/20 0.47
HSD17B10 Q99714 4/20 0.47
GAA P10253 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
GLA P06280 1/20 0.47
RCE1 Q9Y256 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALOX15 P16050 1/20 0.44
CYP4F2 P78329 2/20 0.43
CYP4A11 Q02928 2/20 0.43
TSHR P16473 3/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 2/20 0.40
HTT P42858 1/20 0.40
TBXAS1 P24557 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28833165 0.83 KDM4E (0.48) KDM4EALDH1A1HSD17B10GAAMEN1
SCHEMBL23922797 0.80 KDM4E (0.45) KDM4EALDH1A1HSD17B10GAAMEN1
SCHEMBL9205380 0.77 KDM4E (0.51) KDM4EALDH1A1HSD17B10GAAMEN1
SCHEMBL9207480 0.75 KDM4E (0.56) KDM4EALDH1A1HSD17B10GAAMEN1
SCHEMBL2827984 0.74 ALDH1A1 (0.59) KDM4EALDH1A1HSD17B10GAAMEN1
SCHEMBL28833433 0.72 KDM4E (0.43) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL22114573 0.72 ALDH1A1 (0.56) KDM4EALDH1A1HSD17B10GAAMEN1
SCHEMBL29959857 0.71 KDM4E (0.54) KDM4EALDH1A1HSD17B10GAAMEN1
SCHEMBL22114352 0.71 KDM4E (0.54) KDM4EALDH1A1HSD17B10GAAMEN1
SCHEMBL9202399 0.71 KMT2A (0.45) KDM4EALDH1A1HSD17B10GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12071434-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-08-27 US disclosed
EP-3895707-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2023-10-04 EP disclosed
US-20230042358-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-09 US disclosed
EP-3895707-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2021-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230042358-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NTSR2 KDM4E 1355/4885ALDH1A1 1746/4885HSD17B10 1386/4885
US-12071434-B2 Heterocyclic compound HCRTR2, HCRTR1, NTSR2 KDM4E 1355/4885ALDH1A1 1746/4885HSD17B10 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.